Show simple item record

dc.contributor.authorVinci, M
dc.contributor.authorBurford, A
dc.contributor.authorMolinari, V
dc.contributor.authorKessler, K
dc.contributor.authorPopov, S
dc.contributor.authorClarke, M
dc.contributor.authorTaylor, KR
dc.contributor.authorPemberton, HN
dc.contributor.authorLord, CJ
dc.contributor.authorGutteridge, A
dc.contributor.authorForshew, T
dc.contributor.authorCarvalho, D
dc.contributor.authorMarshall, LV
dc.contributor.authorQin, EY
dc.contributor.authorIngram, WJ
dc.contributor.authorMoore, AS
dc.contributor.authorNg, H-K
dc.contributor.authorTrabelsi, S
dc.contributor.authorH'mida-Ben Brahim, D
dc.contributor.authorEntz-Werle, N
dc.contributor.authorZacharoulis, S
dc.contributor.authorVaidya, S
dc.contributor.authorMandeville, HC
dc.contributor.authorBridges, LR
dc.contributor.authorMartin, AJ
dc.contributor.authorAl-Sarraj, S
dc.contributor.authorChandler, C
dc.contributor.authorSunol, M
dc.contributor.authorMora, J
dc.contributor.authorde Torres, C
dc.contributor.authorCruz, O
dc.contributor.authorCarcaboso, AM
dc.contributor.authorMonje, M
dc.contributor.authorMackay, A
dc.contributor.authorJones, C
dc.date.accessioned2018-05-21T14:35:49Z
dc.date.issued2018-05-01
dc.identifier.citationNature Medicine, 24 (8), pp. 1204 - 1215
dc.identifier.issn1078-8956
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1677
dc.identifier.doi10.1038/s41591-018-0086-7
dc.description.abstractThe failure to develop effective therapies for pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG) is in part due to their intrinsic heterogeneity. We aimed to quantitatively assess the extent to which this was present in these tumors through subclonal genomic analyses and to determine whether distinct tumor subpopulations may interact to promote tumorigenesis by generating subclonal patient-derived models in vitro and in vivo. Analysis of 142 sequenced tumors revealed multiple tumor subclones, spatially and temporally coexisting in a stable manner as observed by multiple sampling strategies. We isolated genotypically and phenotypically distinct subpopulations that we propose cooperate to enhance tumorigenicity and resistance to therapy. Inactivating mutations in the H4K20 histone methyltransferase KMT5B (SUV420H1), present in <1% of cells, abrogate DNA repair and confer increased invasion and migration on neighboring cells, in vitro and in vivo, through chemokine signaling and modulation of integrins. These data indicate that even rare tumor subpopulations may exert profound effects on tumorigenesis as a whole and may represent a new avenue for therapeutic development. Unraveling the mechanisms of subclonal diversity and communication in pGBM and DIPG will be an important step toward overcoming barriers to effective treatments.
dc.format.extent1204 - 1215
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS INC
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.titleFunctional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.
dc.typeJournal Article
dcterms.dateAccepted2018-05-03
rioxxterms.versionofrecord10.1038/s41591-018-0086-7
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-05-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature Medicine
pubs.issue8
pubs.notes6 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Glioma Team
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Glioma Team
pubs.volume24
pubs.embargo.terms6 months
icr.researchteamGlioma Team
dc.contributor.icrauthorClarke, Matthew
dc.contributor.icrauthorMackay, Alan
dc.contributor.icrauthorJones, Chris


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following collection(s)

Show simple item record